cas 1121-25-1|| where to buy 2-methylpyridin-3-ol

Product Name:2-methylpyridin-3-ol

IUPAC Name:2-methylpyridin-3-ol

Packing Unit	Available Stock	Price($)
CM105748-100g	in stock	ȃȃŹ
CM105748-500g	in stock	ůƓŉ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1121-25-1 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1121-25-1; Molecular Formula:C6H7NO; Melting Point:-; Smiles Code:OC1=CC=CN=C1C; Density:

: Catalog Number:CM105748; Molecular Weight:109.13; Boiling Point:; MDL No:MFCD00082538; Storage:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Vimseltinib; Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.